The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. 1992

J Sahai, and K Gallicano, and G Garber, and I McGilveray, and N Hawley-Foss, and N Turgeon, and D W Cameron
Department of Medicine, Ottawa General Hospital, Ontario, Canada.

Eleven HIV-infected men participated in a randomized, two-treatment, two-period crossover study to determine the effect of a 25 g protein meal on zidovudine pharmacokinetics. On two separate occasions, 1 week apart, each patient received 200 mg zidovudine in a fasting state or immediately following the protein meal. A protein meal significantly decreased Cmax [532 (228 s.d.) vs 802 (452 s.d.) ng ml-1, P = 0.004] and increased mean residence time (138 (26 s.d.) vs 114 (26 s.d.) min, corrected for lag times, P = 0.001). However, AUC, tmax, terminal half-life and renal clearance were not significantly altered (P greater than 0.05). The power to detect a 20% change in AUC was 98% at the 5% significance level. In contrast to fat-containing foods, protein-based meals may not alter the extent of zidovudine absorption.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D004044 Dietary Proteins Proteins obtained from foods. They are the main source of the ESSENTIAL AMINO ACIDS. Proteins, Dietary,Dietary Protein,Protein, Dietary
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

J Sahai, and K Gallicano, and G Garber, and I McGilveray, and N Hawley-Foss, and N Turgeon, and D W Cameron
June 2012, Chinese medical journal,
J Sahai, and K Gallicano, and G Garber, and I McGilveray, and N Hawley-Foss, and N Turgeon, and D W Cameron
January 1990, Journal of acquired immune deficiency syndromes,
J Sahai, and K Gallicano, and G Garber, and I McGilveray, and N Hawley-Foss, and N Turgeon, and D W Cameron
January 1995, Blood purification,
J Sahai, and K Gallicano, and G Garber, and I McGilveray, and N Hawley-Foss, and N Turgeon, and D W Cameron
January 1990, Journal of acquired immune deficiency syndromes,
J Sahai, and K Gallicano, and G Garber, and I McGilveray, and N Hawley-Foss, and N Turgeon, and D W Cameron
March 1993, The American journal of psychiatry,
J Sahai, and K Gallicano, and G Garber, and I McGilveray, and N Hawley-Foss, and N Turgeon, and D W Cameron
January 1995, Infection,
J Sahai, and K Gallicano, and G Garber, and I McGilveray, and N Hawley-Foss, and N Turgeon, and D W Cameron
February 1996, Epilepsy research,
J Sahai, and K Gallicano, and G Garber, and I McGilveray, and N Hawley-Foss, and N Turgeon, and D W Cameron
March 2001, The Journal of pharmacy and pharmacology,
J Sahai, and K Gallicano, and G Garber, and I McGilveray, and N Hawley-Foss, and N Turgeon, and D W Cameron
May 2007, European journal of clinical pharmacology,
J Sahai, and K Gallicano, and G Garber, and I McGilveray, and N Hawley-Foss, and N Turgeon, and D W Cameron
May 1990, American family physician,
Copied contents to your clipboard!